Mazorelvimab

Cat. No.: HY-P99727

CAS No.: 2419087-89-9

Target: RABV

Pathway: Anti-infection

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Mazorelvimab (SYN023) is a combination of CTB011 and CTB012 humanized monoclonal antibodies cocktail against rabies virus (RABV). Mezagitamab binds to non-overlapping epitopes on RABV glycoprotein (G). Mezagitamab has potential application in the prevention of rabies[1][2].

In Vitro

Mazorelvimab (0.01-100 μg/mL) shows cytotoxicity to CVS-11 infected BSR cells with dose-dependent manner, but without effecting on uninfected BSR cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mazorelvimab (0.03-1.0 mg/kg; i.m.; single dose) improves the survival rate of rabies virus (RABV) infected hamsters with dose-dependent manner[1].

Mazorelvimab (0.003-1 mg/kg; i.m.; single dose) improves the survival rate of RABV infected hamsters with dose-dependent manner. Mazorelvimab (0.003-0.03 mg/kg) has insignificant interference with the serum RVNA level of Syrian hamsters without virus infection[2].

Mazorelvimab (0.03-1 mg/kg; i.m.; single dose) has protective effect in beagles infected with RABV (BD06)[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	RABV infected Syrian hamster[1].
Dosage:	0.03, 0.1, 0.3 and 1.0 mg/kg.
Administration:	Right gastrocnemius muscle injection; single dose.
Result:	Improved the survival rate.

Animal Model:	10 two-month-old female Syrian hamsters/six-month-old beagles infected with RABV (BD06)[2].
Dosage:	0.003, 0.01, 0.03, 0.1, 0.3 and 1 mg/kg.
Administration:	Right gastrocnemius muscle or masseter muscle injection; single dose.
Result:	Improved survival rate and had protective effect.

REFERENCES

[1]. Chao TY, et al. SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies. PLoS Negl Trop Dis. 2017 Dec 20;11(12):e0006133.

[2]. Chao TY, et al. In Vivo Efficacy of SYN023, an Anti-Rabies Monoclonal Antibody Cocktail, in Post-Exposure Prophylaxis Animal Models. Trop Med Infect Dis. 2020 Feb 21;5(1):31.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA